SEARCH:   Advanced

Blood, 15 May 2008, Vol. 111, No. 10, pp. 5252-5255. Prepublished online as a Blood First Edition Paper on March 31, 2008; DOI 10.1182/blood-2007-10-118141. This Article Full Text (PDF) All Versions of this Article: blood-2007-10-118141v1 111/10/5252    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Heaney, N. B. Articles by Holyoake, T. L. Search for Related Content PubMed PubMed Citation Articles by Heaney, N. B. Articles by Holyoake, T. L. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted October 29, 2007 Accepted March 8, 2008 Complete molecular responses are achieved following reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukaemia Nicholas B. Heaney, Mhairi Copland, Karen Stewart, Judith Godden, Anne N. Parker, I. Grant McQuaker, Graeme M. Smith, Charles Crawley, Pat Shepherd, and Tessa L. Holyoake* Section of Experimental Haematology & Haemopoietic Stem Cells, University of Glasgow, Glasgow, United Kingdom Department of Haematology, Royal Infirmary, Glasgow, United Kingdom Department of Haematology, Leeds General Infirmary, Leeds, United Kingdom Clinical Haematology, Addenbrookes Hospital, Leeds, United Kingdom Western General Hospital, Edinburgh, United Kingdom * Corresponding author; email: tlh1g{at}clinmed.gla.ac.uk. Patients with newly diagnosed chronic phase chronic myeloid leukaemia (CML) were treated with imatinib mesylate (IM), for 6-12 months to establish disease control, prior to reduced intensity stem cell transplantation (RISCT). Escalating doses of donor lymphocyte infusions (DLI) were given from 6 months post-transplant to eradicate residual disease. 18 patients entered the study and 15 received RISCT (median follow up 31 months). RISCT was well tolerated with rapid engraftment, short in-patient stays and few readmissions. Viral reactivation was common, although extensive graft versus host disease (GvHD) occurred infrequently. DLI were given as part of the RISCT protocol in 13/15 patients. BCR-ABL transcripts continue to decrease post-RISCT and 8 (53%) patients have achieved sustained undetectable levels. All patients are currently off IM. Although IM is now established as first-line therapy for chronic phase CML, this protocol is a safe, well tolerated and effective strategy in these patients. This study is registered at http://www.controlled-trials.com as ISRCTN86187144. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Baccarani, M. Dreyling, and On behalf of the ESMO Guidelines Working Group Chronic myelogenous leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv105 - iv107. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020